| Volume 15, Number 17 |
July 26, 2010
|
|
 |
Alcon’s Constellation Vision System recalled |
|
According to the Food and Drug Administration, Alcon (Fort Worth, Texas) has initiated a recall on its Constellation Vision System after identifying both software and hardware problems that have been associated with unexpected system loss of power (shutdowns), unintended system error messages, unresponsive touchscreens, and system setting and infusion performance problems. The FDA noted all model and catalog numbers are affected by the recall. For details of the recall . |
|
|
Hoya, Adoptics partner on accommodating IOLs |
|
Hoya Surgical Optics (Chino Hills, Calif.) and Adoptics (Switzerland) have agreed to co-develop a “shape-changing accommodating IOL,” Hoya said in a press release. “This AIOL technology is based on a novel and clever concept that has the potential to produce a very powerful accommodative effect—something that remains the 'Holy Grail' of cataract and refractive surgery,” said David F. Chang, M.D., clinical professor of ophthalmology, University of California, San Francisco.
Adoptics’ technology uses a proprietary fluid-based refraction system within an IOL to create significant changes in the refractive power of the human visual system. Unlike other presbyopia-correcting IOLs, the Adoptics lens does not require movement of the optic within the eye to change refractive power. The refractive surface of the IOL changes shape in response to movement of the ciliary muscles, the natural process of accommodation in the human eye, said those familiar with the product. |
|
|
NovaVision assets to be sold |
|
NovaVision (Boca Raton, Fla.) filed for bankruptcy in April, and its primary asset, the Visual Restoration Therapy System (VRT), approved for marketing for the treatment of stroke, traumatic brain injury, amblyopia, and optic nerve damage, is now for sale.
VRT treatment has been offered at leading neurological, eye, and rehabilitation centers throughout the U.S. and Europe; the treatment can be prescribed by ophthalmologists, neurologists, or physiatrists. Data from a recent retrospective study showed that more than 70% of U.S. patients who underwent a six-month treatment protocol with NovaVision VRT showed significant improvement in their vision, the company said. The California-based Magnum Group has been contracted to handle inquiries. |
|
|
Generic Flomax granted approval |
|
| A generic version of Flomax (tamsulosin) has been granted approval by U.S. regulators. Sun Pharma (Mumbai) said its tamsulosin 0.4 mg will be marketed by Caraco Pharmaceutical Laboratories (Detroit, Mich.). Tamsulosin is approved for the treatment of the signs and symptoms of benign prostatic hyperplasia (BPH). Its use has been associated with floppy iris syndrome when undergoing cataract surgery. |
|
|
ISCO, Insight Bioventures launch Indian subsidiary |
|
|
|
|
EYEWORLD WEEK Online edited by David Laber and
Enette Ngoei
EyeWorld Week Online (ISSN 1089-0319), a digital publication of the American Society of Cataract and
Refractive Surgery and the American Society of Ophthalmic Administrators, is published every Monday,
distributed by e-mail, and posted live on Monday mornings.
Chief Medical Editors: Stephen A. Obstbaum, M.D., and Stephen S. Lane, M.D.
For sponsorship oppurtunities or membership information, contact:
ASCRS•ASOA • 4000 Legato Rd., • Suite 700 • Fairfax, VA 22033 • Phone:703-591-2220 • Fax: 703-591-0614 •
E-mail: ASCRS
Opinions expressed in EyeWorld Week do not necessarily reflect those of the ASCRS•ASOA.
Mention of products or services does not constitute an endorsement by the ASCRS•ASOA.
|
![[Valid RSS]](images/rss.gif "Subscribe to RSS feed")
